ChemedFRA:CXM +1.03%78 Days Payable is 13.36 as of Mar. 2026, which is 4% below its 10-year median of 13.95. GuruFocus rates FRA:CXM with a GF Score™ of 78/100 and a GF Value™ of €562.39 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 606 Healthcare Providers & Services companies, Chemed ranks worse than 91.42% on this metric.
Chemed's average Accounts Payable for the
three
months ended in Mar. 2026 was €56 Mil. Chemed's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €382 Mil.
Hence, Chemed's Days Payable for the
three
months ended in Mar. 2026 was 13.36.
The historical rank and industry rank for Chemed's Days Payable or its related term are showing as below:
FRA:CXM'
s Days Payable Range Over the Past 10 Years
Min: 11.61 Med: 13.95 Max: 16.96
Current: 11.76
During the past 13 years, Chemed's highest Days Payable was 16.96. The lowest was 11.61. And the median was 13.95.
FRA:CXM's Days Payable is ranked worse than 91.42% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 58.205
vs FRA:CXM: 11.76
Chemed's Days Payable
increased
from Mar. 2025 (9.88) to Mar. 2026 (13.36).
It may suggest that Chemeddelayed paying its suppliers.
Chemed Days Payable Related Terms
Chemed Days Payable Historical Data
* Premium members only.
The historical data trend for Chemed's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CXM vs PACS, OPCH, CON: Days Payable Comparison
For the Medical Care Facilities subindustry, Chemed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemed Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Chemed's Days Payable distribution charts can be found below:
* The bar in red indicates where Chemed's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Chemed's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemed (FRA:CXM) has a Days Payable of 13.36 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chemed and its competitors. This is near median its historical median of 13.95. Over the past decade, Chemed's Days Payable has ranged from 11.61 to 16.96. According to the industry distribution chart, Chemed ranks #554 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 91.4%.
Is Chemed's Days Payable too high?
Chemed's current Days Payable of 13.36 is near median its 10-year median of 13.95. Over the past 10 years, this metric has ranged from a low of 11.61 to a high of 16.96. The Healthcare Providers & Services industry median Days Payable is 58.21. Chemed's value of 13.36 is 77% below this industry median. Based on the distribution chart, Chemed ranks #554 out of 606 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Chemed has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's Days Payable compare to PACS and OPCH?
According to the Healthcare Providers & Services industry distribution chart, Chemed ranks #554 out of 606 companies for Days Payable. This places Chemed in the lower half of its industry. The industry median Days Payable is 58.21. Chemed's value of 13.36 is 77% below this benchmark. Historically, Chemed's own Days Payable has ranged from 11.61 to 16.96 over the past decade. While the company's 10-year median is 13.95 vs. the industry median of 58.21, Chemed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.21, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemed's current Days Payable of 13.36 is 77% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chemed and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemed's current Days Payable is 13.36, which is near median its own 10-year median of 13.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Significantly Undervalued. The stock's GF Value™ is €562.39, compared to a current price of €394.00 — trading 29.9% below its estimated fair value. The current Days Payable is 13.36, which is near median its 10-year median of 13.95 and 77% below the Healthcare Providers & Services industry median of 58.21. Chemed's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chemed (FRA:CXM), the current Days Payable is 13.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemed (FRA:CXM) Overvalued in 2026?
Based on GuruFocus' analysis, Chemed stock appears to be undervalued.
The current stock price of €394.00 is trading 29.9% below its estimated GF Value™ of €562.39.
GuruFocus considers Chemed to be Significantly Undervalued.
Key valuation signals for FRA:CXM:
Days Payable: 13.36 (near median its 10-year median of 13.95)
GF Value™: €562.39 vs. price of €394.00 (29.9% below fair value)
Industry Position: 77% below the Healthcare Providers & Services median (#554 of 606)
No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
78GF Score
Get the complete analysis for FRA:CXM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CXM has been successfully added to your 
